Contribution of phases in the life cycle of different inhaler devices to their individual carbon footprint (net kg CO2e/per pack) and annual carbon footprints of each device
| RELVAR ELLIPTA 92/22 µg | SERETIDE ACCUHALER 50/500 µg | VENTOLIN ACCUHALER 200 µg | SERETIDE EVOHALER 25/250 µg | VENTOLIN EVOHALER 100 µg | |
| Active pharmaceutical ingredients | 0.02 | 0.25 | 0.02 | 0.08 | 0.10 |
| Manufacturing | 0.73 | 0.46 | 0.42 | 2.12 | 1.11 |
| Distribution | 0.03 | 0.06 | 0.02 | 0.03 | 0.02 |
| User phase | 0.00 | 0.12 | 0.12 | 10.68 | 19.39 |
| End of life | 0.03 | 0.01 | 0.01 | 6.08 | 7.38 |
| Net kg CO2e/pack | 0.80 | 0.90 | 0.60 | 19.00 | 28.00 |
| Net kg CO2e/year | 9.5 | 11.0 | 7.3* | 234.0 | 205.0* |
*If using on average two doses per day.